Pituitary adenoma: Difference between revisions

Jump to navigation Jump to search
Line 21: Line 21:


==[[Pituitary adenoma classification|Classification]]==
==[[Pituitary adenoma classification|Classification]]==
Pituitary tumors were, historically, classed as [[basophilic]], [[Acidophile|acidophilic]], or [[chromophobic]] on the basis of whether or not they took up the stains [[hematoxylin]] and [[eosin]]. This classification has fallen into disuse, in favor of a classification based on what type of [[hormone]] is secreted by the tumor (though tumors which do not secrete any active hormone ("non-functioning tumors") are still sometimes called "chromophobic").
At present, classification of pituitary tumors is based on plasma hormone levels or [[immunohistochemical staining]]:
{| class="wikitable"
| '''Type of adenoma''' || '''Secretion''' || '''Staining''' || '''Pathology'''
|-
| ''[[corticotrophic]] adenomas'' ||  secrete adrenocorticotropic hormone ([[ACTH]]) and pro-opiomelanocortin ([[POMC]]) || [[Anterior pituitary basophil|basophilic]] || [[Cushing's disease]]
|-
| ''[[somatotrophic]] adenomas'' ||  secrete growth hormone ([[GH]]) || [[Acidophile (histology)|acidophilic]] || [[acromegaly]] (gigantism)
|-
| ''[[thyrotrophic]] adenomas'' (rare) ||  secrete thyroid-stimulating hormone ([[TSH]]) || [[Anterior pituitary basophil|basophilic]] || occasionally [[hyperthyroidism]]{{ref|thyrotrophic}}, usually doesn't cause symptoms
|-
| ''[[gonadotrophic]] adenomas'' ||  secrete luteinizing hormone ([[LH]]), follicle-stimulating hormone ([[FSH]]) and their subunits || [[Anterior pituitary basophil|basophilic]] || usually doesn't cause symptoms
|-
| ''[[lactrotrophic]] adenomas'' or ''[[prolactinoma]]s'' (most common) ||  secrete [[prolactin]]  || [[Acidophile (histology)|acidophilic]] || [[galactorrhea]], [[hypogonadism]], [[amenorrhea]], [[infertility]], and [[impotence]]
|-
|  ''[[null cell]] adenomas'' || do not secrete hormones || may stain positive for [[synaptophysin]] ||
|}


==Diagnosis==
==Diagnosis==

Revision as of 14:23, 21 January 2012

For patient information click here

Pituitary adenoma
ICD-10 D35.2
ICD-9 237.0
ICD-O: Template:ICDO
MeSH D010911

WikiDoc Resources for Pituitary adenoma

Articles

Most recent articles on Pituitary adenoma

Most cited articles on Pituitary adenoma

Review articles on Pituitary adenoma

Articles on Pituitary adenoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pituitary adenoma

Images of Pituitary adenoma

Photos of Pituitary adenoma

Podcasts & MP3s on Pituitary adenoma

Videos on Pituitary adenoma

Evidence Based Medicine

Cochrane Collaboration on Pituitary adenoma

Bandolier on Pituitary adenoma

TRIP on Pituitary adenoma

Clinical Trials

Ongoing Trials on Pituitary adenoma at Clinical Trials.gov

Trial results on Pituitary adenoma

Clinical Trials on Pituitary adenoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pituitary adenoma

NICE Guidance on Pituitary adenoma

NHS PRODIGY Guidance

FDA on Pituitary adenoma

CDC on Pituitary adenoma

Books

Books on Pituitary adenoma

News

Pituitary adenoma in the news

Be alerted to news on Pituitary adenoma

News trends on Pituitary adenoma

Commentary

Blogs on Pituitary adenoma

Definitions

Definitions of Pituitary adenoma

Patient Resources / Community

Patient resources on Pituitary adenoma

Discussion groups on Pituitary adenoma

Patient Handouts on Pituitary adenoma

Directions to Hospitals Treating Pituitary adenoma

Risk calculators and risk factors for Pituitary adenoma

Healthcare Provider Resources

Symptoms of Pituitary adenoma

Causes & Risk Factors for Pituitary adenoma

Diagnostic studies for Pituitary adenoma

Treatment of Pituitary adenoma

Continuing Medical Education (CME)

CME Programs on Pituitary adenoma

International

Pituitary adenoma en Espanol

Pituitary adenoma en Francais

Business

Pituitary adenoma in the Marketplace

Patents on Pituitary adenoma

Experimental / Informatics

List of terms related to Pituitary adenoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Classification

Diagnosis

The diagnosis is generally entertained either on the basis of visual difficulties arising from the compression of the optic nerve by the tumor, or on the basis of manifestations of excess hormone secretion: the specifics depend on the type of hormone. The specific area of the visual pathway at which compression by these tumours occurs is at the optic chiasma.

The anatomy of this structure causes pressure on it to produce a defect in the temporal visual field on both sides, a condition called bitemporal hemianopia.

Tumors which cause visual difficulty are likely to be macroadenomata greater than 10 mm in diameter; tumors less than 10 mm are microadenomata.

Some tumors secrete more than one hormone, the most common combination being GH and prolactin.

Prolactinomas are frequently diagnosed during pregnancy, when the hormone progesterone increases the tumor's growth rate. Headaches may be present. The diagnosis is confirmed by testing hormone levels, and by radiographic imaging of the pituitary (for example, by CT scan or MRI).

Treatment

Treatment options depend on the type of tumor and on its size:

  • Prolactinomas are most often treated with bromocriptine or more recently, cabergoline which, unlike bromocriptine, decreases tumor size as well as alleviates symptoms, both dopamine agonists, and followed by serial imaging to detect any increase in size. Treatment where the tumor is large can be with radiation therapy or surgery, and patients generally respond well. Efforts have been made to use a progesterone antagonist for the treatment of prolactinomas, but so far have not proved successful.
  • Thyrotrophic adenomas respond to octreotide, a long-acting somatostatin analog, in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.Template:Ref label

References

  1. ^ Template:Note label Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993) Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata. Annals of Internal Medicine 119 (3), 236-240.

See Also

External links

cs:Adenom hypofýzy nl:Hypofysetumor sk:Adenóm hypofýzy sv:Hypofystumör

Template:WikiDoc Sources